» Articles » PMID: 10671921

Management of the Axilla in Operable Breast Cancer Treated by Breast Conservation: a Randomized Clinical Trial. Edinburgh Breast Unit

Overview
Journal Br J Surg
Specialty General Surgery
Date 2000 Feb 15
PMID 10671921
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In the treatment of operable breast cancer by breast conservation, the extent of axillary dissection, the need for radiotherapy to the axilla and the morbidity associated with these procedures have not been assessed adequately.

Methods: Patients with operable breast cancer were randomized to have level III axillary node clearance (232 patients) or axillary node sample (234 patients). Radiotherapy to the axilla was given selectively. Radiotherapy was not given to those who had an axillary clearance. In the early part of the study all patients who had node sample were treated by radiotherapy (54 patients); subsequently this was modified to include only those who were node positive. The morbidity to the shoulder and arm was assessed before and after operation by measuring upper limb volume and circumference, and combined glenohumeral and scapular movement and muscle power.

Results: Comparing the two surgical policies, no difference was found in local (axillary clearance 14 versus sample 15), axillary (eight versus seven) or distant (29 versus 29) recurrence. There was no statistically significant difference in 5-year survival rate (clearance 82.1 versus sample 88.6 per cent). Morbidity was least in those who had a node sample and no radiotherapy to the axilla. Radiotherapy to the axilla in patients who had a node sample resulted in a significant reduction in range of movement of the shoulder, e.g. mean(s.e.) 2.2(0.6) cm reduction in lateral rotation at 3 years. Surgical axillary clearance was associated with significant lymphoedema of the upper limb, e.g. 4.1(0.7) per cent increase in arm volume at 3 years.

Conclusion: A selective policy for the management of the axilla is associated with no increase in axillary recurrence or mortality rate compared with routine axillary node clearance. Patients who are node negative after axillary sample can avoid radiotherapy or axillary clearance.

Citing Articles

A Network Meta-Analysis of Surgical Treatment in Patients With Early Breast Cancer.

Gui Y, Liu X, Chen X, Yang X, Li S, Pan Q J Natl Cancer Inst. 2019; 111(9):903-915.

PMID: 31187142 PMC: 6748720. DOI: 10.1093/jnci/djz105.


Changes in Pectoral Muscle Volume During Subacute Period after Radiation Therapy for Breast Cancer: A Retrospective up to 4-year Follow-up Study.

Seo A, Hwang J, Lee J, Jung T Sci Rep. 2019; 9(1):7038.

PMID: 31065026 PMC: 6505029. DOI: 10.1038/s41598-019-43163-0.


Axillary treatment for operable primary breast cancer.

Bromham N, Schmidt-Hansen M, Astin M, Hasler E, Reed M Cochrane Database Syst Rev. 2017; 1:CD004561.

PMID: 28052186 PMC: 6464919. DOI: 10.1002/14651858.CD004561.pub3.


Incidental irradiation of internal mammary lymph nodes in breast cancer: conventional two-dimensional radiotherapy versus conformal three-dimensional radiotherapy.

Leite E, Ugino R, Santana M, Ferreira D, Lopes M, Pelosi E Radiol Bras. 2016; 49(3):170-5.

PMID: 27403017 PMC: 4938447. DOI: 10.1590/0100-3984.2015.0003.


Role of Combined Sentinel Lymph Node Biopsy and Axillary Node Sampling in Clinically Node-Negative Breast Cancer.

Edwards K, Dordea M, French R, Kurup V Indian J Surg. 2016; 77(6):495-501.

PMID: 26884657 PMC: 4744230. DOI: 10.1007/s12262-015-1300-1.